We are live on
!
Find out more
BSA
Braun Stacey Associates Portfolio holdings
AUM
$3.01B
1-Year Est. Return
47.79%
This Fund
S&P 500
This Quarter
Est. Return
+18.84%
1 Year Est. Return
+47.79%
3 Year Est. Return
+184.24%
5 Year Est. Return
+273.21%
10 Year Est. Return
+1,255.9%
AUM
$2.76B
AUM Growth
+$318M
(+13%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
0.12%
Top 10 Holdings %
Top 10 Hldgs %
33.65%
Holding
126
New
10
Increased
35
Reduced
63
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CME Group
CME
|
+$24.5M |
| 2 |
Netflix
NFLX
|
+$23.9M |
| 3 |
Quest Diagnostics
DGX
|
+$23.6M |
| 4 |
QXO
QXO Inc
QXO
|
+$20.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$19.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$21.7M |
| 2 |
Marvell Technology
MRVL
|
+$15.5M |
| 3 |
UnitedHealth
UNH
|
+$14.4M |
| 4 |
Trade Desk
TTD
|
+$14M |
| 5 |
Howmet Aerospace
HWM
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.99% |
| 2 | Financials | 14.25% |
| 3 | Communication Services | 11.45% |
| 4 | Industrials | 9.49% |
| 5 | Healthcare | 9.22% |
Similar funds
CI
BGDI
ROTUOC
KIA
PCM
TAM
DIG
Braun Stacey Associates's Q2 2025 Portfolio in Review
As of Q2 2025, Braun Stacey Associates held 126 positions worth $2.76B, up 13% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Braun Stacey Associates's Q2 2025 filing shows 10 new, 35 increased, 63 reduced and 14 closed positions. Its largest new stake was CME Group: 89,918 shares worth $24.8M. The largest sale was Vertex Pharmaceuticals, an estimated $21.7M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Financials and Communication Services.
- Braun Stacey Associates's largest Q2 2025 buy was CME Group: 89,918 shares worth $24.8M.
- Braun Stacey Associates added most to Celsius Holdings in Q2 2025, an estimated $13.6M increase.
- Braun Stacey Associates's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $14.4M.
- Braun Stacey Associates fully exited Vertex Pharmaceuticals in Q2 2025, selling an estimated $21.7M.
- Braun Stacey Associates's ten largest holdings make up 34% of its $2.76B portfolio in Q2 2025.
- Braun Stacey Associates opened 10 new positions and closed 14 in Q2 2025.
- Braun Stacey Associates's portfolio value rose 13% quarter-over-quarter to $2.76B.
Based on Braun Stacey Associates's 13F filing for Q2 2025, filed 12 Aug 2025.